ConductScience.org, home
A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy
API referenceFor AI assistants

Trial · NCT01940887

Adverse events202

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

41 to 60 of 202

Download this page as JSON
TypeEventOrgan systemGroupAffectedAt riskEvents
seriousIridocyclitisEye disordersE10030 + Bevacizumab or Aflibercept13221
seriousIridocyclitisEye disordersSham + Bevacizumab or Aflibercept03200
seriousMacular holeEye disordersE10030 + Bevacizumab or Aflibercept13221
seriousMacular holeEye disordersSham + Bevacizumab or Aflibercept03200
seriousRetinal detachmentEye disordersE10030 + Bevacizumab or Aflibercept13222
seriousRetinal detachmentEye disordersSham + Bevacizumab or Aflibercept13202
seriousRetinal haemorrhageEye disordersE10030 + Bevacizumab or Aflibercept23223
seriousRetinal haemorrhageEye disordersSham + Bevacizumab or Aflibercept03200
seriousVitreous haemorrhageEye disordersE10030 + Bevacizumab or Aflibercept03220
seriousVitreous haemorrhageEye disordersSham + Bevacizumab or Aflibercept13201
seriousDuodenal ulcerGastrointestinal disordersE10030 + Bevacizumab or Aflibercept13221
seriousDuodenal ulcerGastrointestinal disordersSham + Bevacizumab or Aflibercept03200
seriousDuodenal ulcer haemorrhageGastrointestinal disordersE10030 + Bevacizumab or Aflibercept13221
seriousDuodenal ulcer haemorrhageGastrointestinal disordersSham + Bevacizumab or Aflibercept03200
seriousDysphagiaGastrointestinal disordersE10030 + Bevacizumab or Aflibercept13221
seriousDysphagiaGastrointestinal disordersSham + Bevacizumab or Aflibercept03200
seriousGastric dysplasiaGastrointestinal disordersE10030 + Bevacizumab or Aflibercept13221
seriousGastric dysplasiaGastrointestinal disordersSham + Bevacizumab or Aflibercept03200
seriousGastrointestinal haemorrhageGastrointestinal disordersE10030 + Bevacizumab or Aflibercept13221
seriousGastrointestinal haemorrhageGastrointestinal disordersSham + Bevacizumab or Aflibercept13201

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Previous pageNext page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01940887/events?page=3

API referenceFor AI assistants